Maraviroc is the amazing medicinal preparation developed, manufactured and distributed by world’s one of the leading pharmaceutical company known as Pfizer. The medication is prepared for the treatment of HIV which considerably diminishes the viral load in combination therapy across the range of treatment experienced patients. The drug is formulated by using the active pharmaceutical ingredient known as Celsentri which is the tentative entry inhibitor that is being developed by Pfizer. The drug has not yet been assessed by the U.S. Food and Drug Administration – FDA for use by the patients living with the HIV syndromes.   

Maraviroc bind to the typical protein on the membrane of CD4 cells – T-cells known as CCR5. Once this is successfully done then the HIV cannot bind with the surface of the CD4 cells thoroughly, as the result of which the HIV viruses are unable to infect the other healthy cells in the body. Maraviroc is most likely to be used in combination with certain anti-HIV drugs. The authentic dose of Maraviroc has not yet been determined. During the phase 3 clinical trials, once as well as twice per day doses were tested. When it was combined with HIV medications like protease inhibitors and several non-nucleoside reserve transcriptase inhibitors that resulted in drug interactions with Maraviroc, the Maraviroc dose would likely be 150mg; in general the same would be 300mg.

During one particular study, 54 HIV negative volunteers took either 100mg or 300mg of this wonder medication Maraviroc or Celsentri twice per day for the period of 28 days. None of the severe or any serious adverse affects were reported by any of the 54 HIV volunteers during the entire time frame of the study. However, more detailed information related to the long term safety and possible side effects of the medicine Maraviroc or Celsentri in HIV positive patients are yet not available.